What is it about?
In patients with Homozygous Familial Hypercholesterolemia, therapy starts at so young an age that it is imperative to balance the short-term lipid target with the long-term negative effects of therapy. A ‘personalized’ therapeutic regimen, aimed at quoad valetudinem, allowed for social cost reduction, complete regression of lipid deposition and an acceptable patient quality of life.
Photo by ipet photo on Unsplash
Why is it important?
we described a personalized therapeutic regimen as a paradignatic case management in Homozygous Familial Hypercholesterolemia aimed at life saving and acceptable quality of life.
Read the Original
This page is a summary of: Null receptor homozygous familial hypercholesterolaemia: Quoad valetudinem long life treatment, European Journal of Preventive Cardiology, July 2019, SAGE Publications, DOI: 10.1177/2047487319864191.
You can read the full text:
The following have contributed to this page